SweeGen#s non-GMO Reb M Stevia Leaf Sweetener Approved in Singapore

Food and Healthcare Press Releases Friday August 9, 2019 08:35
RANCHO SANTA MARGARITA, California--9 Aug--PRNewswire/InfoQuest
Food and Drink manufacturers' answer to Singapore's proposed "Sugar Tax"
SweeGen, Inc., a nature-based sweetener company, announced the Singapore Food Agency has added SweeGen's Reb M Stevia Leaf Sweetener to the list of permitted food additives.
SweeGen's Reb M is a non-caloric stevia sweetener that provides sweetness with a clean, sugar-like taste and now enables food and beverage manufacturers to reduce sugar, without sacrificing taste.

This approval comes at a time when Singapore is considering a "sugar tax" hoping to change the behaviors of consumers and manufacturers on reducing sugar-based products. Earlier this year, Singapore's Ministry of Health (MOH) proposed multiple measures potentially impacting the food and beverage sectors including banning the sale of higher sugar drinks and imposing a tax on sugar-based drinks.

SweeGen's unique production starts with the stevia leaf and uses a patented bioconversion process to achieve high purity, clean-tasting Reb M. This process enabled SweeGen to obtain the Non-GMO Project verification for Reb M, which was commercialized in 2017 and has been approved in many regions around the world.

"We are excited to introduce our non-GMO Reb M stevia leaf sweetener to food and beverage manufacturers in Singapore," said Lewis Tessarolo, senior director of business development Asia Pacific, SweeGen. "Consumer demand for zero and reduced-sugar products is on the rise globally, and our non-GMO Reb M provides a solution to manufacturers."

Reb M, together with Reb D and e+ is part of SweeGen's non-GMO stevia sweetener portfolio. Consumer demand for zero and reduced-sugar products is on the rise globally, and nature-based stevia sweeteners provide a great tasting alternative to sugar and artificial sweeteners.

About SweeGen

SweeGen, Inc. is dedicated to the development, production and distribution of non- caloric sweeteners for the food, flavor and beverage industries. SweeGen's robust product pipeline, intellectual property portfolio, and dedicated manufacturing capacity and R&D provide the foundation for innovation and delivery of high-quality sweeteners. For more information please contact info@sweegen.com and visit SweeGen's website, www.sweegen.com.

Cautionary Statement Concerning Forward-Looking Statements

This press release contains forward-looking statements, including, among other statements, statements regarding the future prospects for Reb M stevia leaf sweetener. These statements are based on current expectations, but are subject to certain risks and uncertainties, many of which are difficult to predict and are beyond the control of SweeGen, Inc.

Relevant risks and uncertainties include those referenced in the historic filings of SweeGen, Inc. with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from those expressed in or implied by the forward-looking statements, and therefore should be carefully considered. SweeGen, Inc. assumes no obligation to update any forward-looking statements as a result of new information or future events or developments.

Logo - https://mma.prnewswire.com/media/469549/Sweegen_Final_OT_Logo.pdf

Latest Press Release

Mindray Chairman's Statement on Efforts to Combat COVID-19

Mindray (SZSE: 300760) -- As COVID-19 is casting a dark shadow over people's health, healthcare providers around the world are fighting relentlessly against the virus. We salute all medical staff for their valiant efforts to save patients' lives and...

CROMSOURCE Announces Launch of COVID-19 Clinical Trial

CROMSOURCE, an international contract research organization (CRO) with its global headquarters in Verona, Italy, has announced that it has initiated its first COVID-19 trial on behalf of a European pharmaceutical company. This trial is expected to be...

HOYA/PENTAX Medical Issues Statement Regarding U.S. Department of Justice Settlement

HOYA Corporation and a subsidiary through PENTAX Medical division, Pentax of America, Inc. (collectively, "PENTAX" or "the Company"), today finalized a Deferred Prosecution Agreement (DPA) with the U.S. Department of Justice (DOJ) on issues related to...

Caviarlieri: The World's Only Caviar Food Supplement with the Latest Innovation in Swiss Cellular Therapy Technology

Encapsulating the potent bioactive nutrients of Caviar into a supplement has been a dream and a formidable challenge for the Anti-Aging Medical World for several decades. Caviarlieri Limited, through its global panel of Anti-Aging medical experts has...

Coping With the Coronavirus, Rambam Healthcare Campus in Israel Joins Forces With Elbit Systems to Deploy a Management & Control Technology

The Rambam Healthcare Campus ("Rambam") in Haifa, Israel starts operating EX-TEAMS, a cellular based management and control system that was jointly developed with Elbit Systems. EX-TEAMS is based on an Elbit Systems' Command & Control (C2) technology...

Related Topics